Key facts
- atDose’s last known valuation is $36.9M (Dec 2024).
- It has raised $4.1M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Japan External Trade Organization, FASTAR, DEFTA Partners, J-StarX.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for atDose
- ·The full record, as it builds
Funding rounds
No funding rounds for atDose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About atDose
Developer of a mobile dosing and infusion device designed to change the treatment methods for serious illnesses. The company's device directly administers the drug to the affected area by combining a microneedle and an electroosmotic flow pump as used in acupuncture and moxibustion treatment, enabling cancer patients to reduce their physical burden, which is caused by the side effects of drugs.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2017
- Employees
- 3
- Website
- atdose.com/
- Ownership
- Privately Held (backing)
atDose doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in atDose shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on atDose in its N-PORT filings yet. We sweep new filings monthly.